Congress Materials - European Hematology Association (EHA 2024)
2024 European Hematology Association | Jun 13-16 | Madrid, Spain
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
6-Year Time to Next Treatment (TTNT) Extrapolation Curve for GLOW Study: First-Line Ibrutinib + Venetoclax (I+V) Offers Long Treatment-Free Period for Elderly/Unfit CLL Patients
Santiago Osorio Prendes, Vicente Gimeno, Jose Angel Hernandez Rivas, Francisco Javier Lopez Jimenez, Joris Diels, Claudio A. Schioppa, Ana Alfayate Lobo, Teresa Domínguez-Lubillo
A Phase 1b Study of the Menin-KMT2A Inhibitor Bleximenib (JNJ-75276617) in Combination with Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia with Alterations in KMT2A or NPM1
Andrew H. Wei, Emma Searle, Ibrahim Aldoss, Ana Alfonso-Piérola, Juan Manuel Alonso-Dominguez, Martin Curtis, Nikki Daskalakis, Matteo G. Della Porta, Hartmut Döhner, Amber D’Souza, James P. Dugan, Jordi Esteve, Matthew Exum, Amir T. Fathi, Pasquale L. Fedele, Lucille Ferrante, Stan Gaj, Ana Garrido Díaz Christina Guttke, Emmanuel Gyan, Brett Hiebert, Elias Jabbour, Madlen Jentzsch, Marina Konopleva, Jan Krönke, Min Chul Kwon, Oliver Lomas, Valentina Mancini, Ioannis Mantzaris, Giovanni Martinelli, Jenny O’Nions, Kathryn Packman, Cristina Papayannidis, Ulrike Philippar, Christian Recher, Christoph Röllig, Olga Salamero, Madhu Sanga, Tim Sauer, Trevor Tucker, Nicolas Vallet, Paresh Vyas, Sylvain Garciaz
Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patient Demographics and Patient-Reported Burden in Ibrutinib and Non-Ibrutinib Receivers in the US: A Real-World Study
Michael Choi, Neil Milloy, Amber Simpson, Rodrigo Maegawa, Zaina Qureshi, Javier Pinilla-Ibarz
Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D
Wilfried Roeloffzen, Tessa Kerre, Mounzer Agha, Michel Delforge, Ira Braunschweig, Nishi Shah, Shambavi Richard, Melissa Alsina, Hermann Einsele, Pankaj Mistry, Helen Varsos, Christina Corsale, Jordan M. Schecter, Kevin C. De Braganca, Yogesh Jethava, Qingxuan Song, Tamar Lengil, Mythili Koneru, Muhammad Akram, Yaël C. Cohen, Bertrand Arnulf
Ciltacabtagene Autoleucel vs Standard of Care in Lenalidomide-Refractory Multiple Myeloma: Phase 3 CARTITUDE-4 Subgroup Analysis by Cytogenetic Risk
Roberto Mina, Binod Dhakal, Jesús San-Miguel, Mi Kwon, Duncan Purtill, Hila Magen, Magdalena Dutka, Michel Delforge, Ravi Vij, Stina Wichert, Sung-Soo Yoon, Monique C. Minnema, Nikoletta Lendvai, Carolina Lonardi, Ana Slaughter, Martin Vogel, Katherine Li, Diana Chen, Man Zhao, Tzu-min Yeh, Nina Benachour, Tamar Lengil, Mythili Koneru, Nitin Patel, Erika Florendo, Octavio Costa Filho, Hermann Einsele, Salomon Manier, Joaquin Martinez-Lopez
Ciltacabtagene Autoleucel vs Standard of Care in Patients With Functional High-Risk Multiple Myeloma: CARTITUDE-4 Subgroup Analysis
Katja Weisel, Luciano J. Costa, Niels W.C.J. van de Donk, Surbhi Sidana, Yaël C. Cohen, Duncan Purtill, Cyrille Touzeau, Carlos Fernández de Larrea, Joaquin Martinez-Lopez, Nikoletta Lendvai, Ana Slaughter, Carolina Lonardi, Man Zhao, Katherine Li, Martin Vogel, Mythili Koneru, Nitin Patel, Erika Florendo, Octavio Costa Filho, María-Victoria Mateos
Clinical Biomarkers Associated With Progression Free Survival to Ciltacabtagene Autoleucel in Chinese Patients With Relapsed/Refractory Multiple Myeloma From the CARTIFAN-1 Study
Ming Hao, Feng Wang, Jian-qing Mi, Fan Yang, Rocio Montes de Oca, Hang Fu, Dianna Wu, Cuc Davis, Hui Li, Wanhong Zhao, Hongmei Jing, Weijun Fu, Ting Niu, Jie Jin, Lijuan Chen, Jianda Hu, Juan Du, Yiwen Zhang, Shuyu Xiong, Wenjie Wang, Da Xu, Denis Smirnov, Sai-juan Chen, Longen Zhou, Vicki Plaks
Comparative Effectiveness of Ciltacabtagene Autoleucel From the CARTITUDE-4 Trial vs Real-World Physician's Choice of Therapy From the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma
Cyrille Touzeau, Brea Lipe, Abdullah M. Khan, Binod Dhakal, Sandhya Nair, Jianming He, Seina Lee, Carolina Lonardi, Ana Slaughter, Nikoletta Lendvai, Jordan M. Schecter, Diana Chen, Man Zhao, Tzu-min Yeh, Xavier Leleu, Noemi Puig, Dominik Dytfeld, Elena Zamagni, Katja Weisel, Lionel Karlin, Michel Delforge, Paolo Corradini, Roberto Mina, Wilfried Roeloffzen, Surbhi Sidana
Comparative Effectiveness of Ibrutinib Flexible Dosing Treatment Strategies on Time to Next Treatment in a Largely Community-Based Claims Database: A Target Trial Emulation Study
Nilanjan Ghosh, Ruibin Wang, Zhijie Ding, Jinghua He, Alex Bokun, Heena Mavani, Zaina P. Qureshi, Kerry A. Rogers
Comparison of Time to Next Treatment Between Patients With Chronic Lymphocytic Leukemia Initiating First-Line Ibrutinib or Acalabrutinib Overall and in a Subgroup With High-Risk Characteristics
Ryan Jacobs, Moshe Y. Levy, Victor Yazbeck, Marie-Hélène Lafeuille, Bruno Emond, Priyanka Gogna, Rodrigo Maegawa, Zaina P. Qureshi, Alessandra Ferrajoli
Cross-Study Comparison of Ibrutinib in Combination with Venetoclax (I+V) versus Venetoclax in Combination with Obinutuzumab (V+G) in Subjects with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Comorbidities
Francisco Javier Lopez Jimenez, Jose Angel Hernandez Rivas, Suzy Van Sanden, Joris Diels, Liva Andersone
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Analysis of Minimal Residual Disease in the PERSEUS Trial
Pieter Sonneveld, Philippe Moreau, Meletios A. Dimopoulos, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Christoph Driessen, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Joan Bladé, Mario Boccadoro, Paula Rodriguez-Otero
Daratumumab (DARA)/ Bortezomib/Lenalidomide/ Dexamethasone (D-VRd) With D-R Maintenance in Transplant-eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Analysis of PERSEUS Based on Cytogenetic Risk
Meletios A. Dimopoulos, Pieter Sonneveld, Paula Rodriguez-Otero, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Christoph Driessen, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie MJ van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Joan Bladé, Mario Boccadoro, Philippe Moreau
Daratumumab (DARA) + Bortezomib/Thalidomide/Dexamethasone (D-VTd) Followed by DARA Maintenance in Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): >6-Year Update of CASSIOPEIA
Philippe Moreau, Cyrille Hulin, Aurore Perrot, Bertrand Arnulf, Karim Belhadj, Lotfi Benboubker, Sonja Zweegman, Hélène Caillon, Denis Caillot, Hervé Avet-Loiseau, Michel Delforge, Thomas Dejoie, Thierry Facon, Cécile Sonntag, Jean Fontan, Mohamad Mohty, Kon-Siong Jie, Lionel Karlin, Frédérique Kuhnowski, Jérôme Lambert, Xavier Leleu, Margaret Macro, Frédérique Orsini-Piocelle, Murielle Roussel, Jean Marc Schiano de Colella, Niels W.C.J. van de Donk, Soraya Wuillème, Annemiek Broijl, Cyrille Touzeau, Mourad Tiab, Jean-Pierre Marolleau, Nathalie Meuleman, Marie-Christiane Vekemans, Matthijs Westerman, Saskia K. Klein, Mark-David Levin, Fritz Offner, Martine Escoffre-Barbe, Jean-Richard Eveillard, Réda Garidi, Winnie Hua, Jianping Wang, Alba Tuozzo, Carla J. de Boer, Melissa Rowe, Veronique Vanquickelberghe, Robin Carson, Jessica Vermeulen, Jill Corre, Pieter Sonneveld
Dose Adjustment Outcomes in Patients With Waldenström Macroglobulinemia Treated With Ibrutinib
Shayna Sarosiek, Stephen P. Treon, M. Lia Palomba, Meletios-Athanasios Dimopoulos, Jorge J. Castillo, Hillary M. Peltier, Vincent Girardi, Alex Bokun, Anat Raz, Michelle Pacia, Christian Buske
Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma and TP53 Mutations in the SYMPATICO Study
Wojciech Jurczak, Michael Wang, Marek Trneny, David Belada, Tomasz Wrobel, Nilanjan Ghosh, Mary-Margaret Keating, Tom van Meerten, Ruben Fernandez Alvarez, Gottfried von Keudell, Catherine Thieblemont, Frederic Peyrade, Marc Andre, Marc Hoffmann, Maoko Naganuma, Edith Szafer-Glusman, Jennifer Lin, James P. Dean, Jutta K. Neuenburg, Constantine S. Tam
Efficacy and Safety of Talquetamab in Chinese Patients With Relapsed/Refractory Multiple Myeloma From the Phase 1/2 MonumenTAL-1 Study
Gang An, Jie Jin, Zhen Cai, Hongmei Jing, Chengcheng Fu, Pengcheng He, Zhongjun Xia, Rui Liu, Liang Li, Xue Gai, Hong Zhang, Dian Zhu, Xinchao Luo, Binbin Sun, Hongmei Xu, Longen Zhou, Michela Campagna, Tara J. Masterson, Bonnie W. Lau, Thomas Renaud, Christoph Heuck, Indrajeet Singh, Deeksha Vishwamitra, Lugui Qiu
Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma With High-Risk Features: A Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study
Luciano J. Costa, Nizar J. Bahlis, Saad Z. Usmani, Niels W.C.J. van de Donk, Ajay K. Nooka, Aurore Perrot, Keqin Qi, Caroline Hodin, Clarissa Uhlar, Athena Zuppa, Katherine Chastain, Margaret Doyle, María-Victoria Mateos
Epidemiology and Real-World Management of Monoclonal Gammopathies Patients in Spain Based on Natural Language Processing and Machine Learning Techniques, the CIMMA Study
Maria Victoria Mateos, Fernando Escalante, Natalia Marin Huarte, Angela García, Miguel Villanueva, Rafael Ríos Tamayo, Antonia Sampol Mayol, Eugenio Giménez, José Ángel Hernandez Rivas, Savana Research Group, and Joaquin Martinez-Lopez
Exploratory Analysis to Identify Response-Related Biomarkers in the China Cohort of the Phase 1/2 MajesTEC-1 Trial of Teclistamab for Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
Hongmei Xu, Feng Wang, Deeksha Vishwamitra, Han Yang, Cuc Davis, Boominathan Rengasamy, Dianna Wu, Zhuolu Niu, Yang Song, Juanjuan Song, Natalia A. Quijano Cardé, Yue Guo, Katherine Chastain, Ting Niu, Weijun Fu, Juan Du, Raluca I. Verona, Ricardo Attar, Longen Zhou
Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Jan Burger, Paul Barr, Tadeusz Robak, Carolyn Owen, Alessandra Tedeschi, Anita Sarma, Piers E. M. Patten, Sebastian Grosicki, Helen McCarthy, Fritz Offner, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, Lynne Neumayr, James P. Dean, Paolo Ghia, Thomas J. Kipps
Final Survival Analysis of Daratumumab Plus Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: MAIA Study
Thierry Facon, Shaji K. Kumar, Robert Z. Orlowski, Nizar Bahlis, Philippe Moreau, Hartmut Goldschmidt, Supratik Basu, Cyrille Hulin, Sonja Zweegman, Katja Weisel, Aurore Perrot, Caroline Jacquet, Noopur Raje, Salomon Manier, Ajai Chari, Markus Hansson, Mohamad Mohty, Michel Delforge, Torben Plesner, Gordon Cook, Xavier Leleu, Hang Quach, Christopher P. Venner, Mourad Tiab, Margaret Macro, Laurent Frenzel, George Wang, Huiling Pei, Kasey Bolyard, Robin Carson, Fredrik Borgsten, Saad Z. Usmani
First-Line Ibrutinib in Patients With Chronic Lymphocytic Leukemia Demonstrates Overall Survival Comparable to an Age-Matched European Population
Paolo Ghia, Alessandra Tedeschi, Loïc Ysebaert, Ann Janssens, Mohamed Fouad, Claudio A. Schioppa, José Ángel Hernández-Rivas
IBROMICS: A Real-World Study of Clinical and Biological Parameters Determining Response in Patients With Chronic Lymphocytic Leukemia (CLL) Treated in First Line With Single Agent Ibrutinib
José-Ángel Hernández-Rivas, Francesc Bosch, Cecilia Muñoz, Laura Palomo, Adrián Mosquera, Ángel Ramírez Payer, Rubén Fernández, Ana Oliveira, Paula Amat, Alicia Serrano, Aránzazu García-Grande, Ana Yeguas, Marta Crespo, Miguel Bastos, Blanca Ferrer, José García-Vela, Luis Espinosa-Hevia, Eva Rubio Azpeitia, Miguel Jesús Villanueva Forero
Indirect Treatment Comparisons of Daratumumab-Pomalidomide-Dexamethasone and Pomalidomide-Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma
Wee Joo Chng, David Bin-Chia Wu, Cathy Kwang-Wei Wu, Lee Anne Rothwell, Sung-Hoon Jung
Longer-Term Follow-Up of Patients Receiving Prophylactic Tocilizumab for Reduction of Cytokine Release Syndrome in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma
Katarina Uttervall, Niels W.C.J. van de Donk, Alfred L. Garfall, Lotfi Benboubker, Kaz Groen, Laura Rosiñol, Jeffrey V. Matous, Deeksha Vishwamitra, Caroline Hodin, Tara Stephenson, Keqin Qi, Athena Zuppa, Katherine Chastain, María-Victoria Mateos
Long-Term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
Leo Rasche, Carolina Schinke, Cyrille Touzeau, Monique C. Minnema, Niels W.C.J. van de Donk, Paula Rodríguez-Otero, María-Victoria Mateos, Jing Christine Ye, Deeksha Vishwamitra, Indrajeet Singh, Xiang Qin, Michela Campagna, Tara Masterson, Brandi W. Hilder, Jaszianne Tolbert, Thomas Renaud, Christoph Heuck, Colleen Kane, Ajai Chari
Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
Albert Oriol, Rakesh Popat, Alfred L. Garfall, Ajay K. Nooka, Niels W.C.J. van de Donk, Philippe Moreau, Manisha Bhutani, Thomas G. Martin, Laura Rosiñol, María-Victoria Mateos, Nizar J. Bahlis, Britta Besemer, Joaquin Martinez-Lopez, Amrita Y. Krishnan, Michel Delforge, Lin Huang, Deeksha Vishwamitra, Tara Stephenson, Katherine Chastain, Surbhi Sidana
Outcomes in High-Risk Subgroups After Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Up to 5.5 Years of Follow-Up in the Phase 2 CAPTIVATE Study
Ryan Jacobs, William G. Wierda, Paul M. Barr, John N. Allan, Tanya Siddiqi, Alessandra Tedeschi, Thomas J. Kipps, Susan M. O'Brien, Xavier C. Badoux, Andrea Visentin, Masa Lasica, Dennis Carney, Anna Elinder Camburn, Javier De la Serna, Edith Szafer-Glusman, Cathy Zhou, Anita Szoke, James P. Dean, Constantine S. Tam, Paolo Ghia
Outcomes of Patients With Extramedullary Disease and Relapsed or Refractory Multiple Myeloma From Historical Clinical Trials
Shaji Kumar, Saad Z. Usmani, Jing Christine Ye, Yaël C. Cohen, Peter M. Voorhees, Emma Scott, Robin L. Carson, Christoph Heuck, Ryan Gan, Colleen Kane, Eleanor Caplan, Hemanth Kanakamedala, Trilok Parekh, María-Victoria Mateos
Real-Life Outcomes in Patients With BCMA-Exposed Relapsed/Refractory Multiple Myeloma Treated With Standard of Care in the LocoMMotion and MoMMent Studies
Katja Weisel, Britta Besemer, Salomon Manier, Hartmut Goldschmidt, Niels W.C.J. van de Donk, Hermann Einsele, Aurore Perrot, Raphael Teipel, Lionel Karlin, Christof Scheid, Charlotte Pawlyn, Joaquín Martínez López, Michele Cavo, Claire Albrecht, Lorenzo Acciarri, Imène Haddad, Vadim Strulev, Kathleen Gray, Margaret Doyle, Philippe Moreau, María-Victoria Mateos
Real-World Clinical Outcomes of First-Line Ibrutinib Dose Reduction Versus Acalabrutinib Among Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayzar Shadman, Sudeep Karve, Christopher Abbazio, Zahra Majd, Shaffee Bacchus, Chadi Saifan, Priyanka Gogna, Ameur M. Manceur, Marie-Hélène Lafeuille, Bruno Emond, Bhavini P. Srivastava, Deborah M. Stephens
Real-World Less Frequent Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma
Carlyn Rose Tan, Andriy Derkach, Kylee Maclachlan, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Sridevi Rajeeve, Gunjan Shah, Michael Scordo, David Chung, Heather J. Landau, Sergio A. Giralt, Alexander Lesokhin, Neha Korde, Dee Lin, Bingcao Wu, Jessica Fowler, Mariana Fernandez, Saad Z. Usmani
Real-World Less Frequent Dosing Schedule of Teclistamab in Patients With Relapsed or Refractory Multiple Myeloma – A US National Healthcare Claims Analysis
Matthew J. Pianko, Jinghua He, Dee Lin, Hsien-Yen Chang, Nina Kim, Jennifer S. Harper, Jessica Fowler, Mariana Fernandez, Margaret Doyle, Laura Hester, Dina Gifkins, Bingcao Wu
Real-World Observations on the Evolving Treatment Landscape and Improved Survival Outcomes for Multiple Myeloma Patients in Finland
Anu Partanen, Johanna Vikkula, Marika Waltari, Riikka Mattila, Katja Närhi, Jonna Eeva, Mervi Putkonen
Real-World Treatment Patterns, Efficacy, and Safety of Daratumumab-Based Regimens in Chinese Patients With Multiple Myeloma: An Updated Analysis of the MMY4032 Study
Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Canchan Cui, Jin Lu
Results From Safety Run-In Cohort 1 of the Phase 3 MajesTEC-7 Study in Patients With Transplant Ineligible/Not Intended Newly Diagnosed Multiple Myeloma
Niels W.C.J. van de Donk, Cyrille Touzeau, Meral Beksac, Evangelos Terpos, Saad Z. Usmani, Amrita Y. Krishnan, Inger S. Nijhof, Wojciech Janowski, Cyrille Hulin, Sebastian Grosicki, Michel Delforge, Dana McAleer, Sarah Nagle, Sarah Broskin, Yunsi Olyslager, Jonathan Miller, Zoe Craig, Josephine Khan, Tobias Kampfenkel, Salomon Manier
Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination With Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma: Safety and Efficacy Results From the Phase 1b MonumenTAL-2 Study
Emma Searle, Hang Quach, Noa Biran, Aurore Perrot, Jesus G. Berdeja, Kathleen Dorritie, Catharina Van Elssen, Cyrille Touzeau, Sébastien Anguille, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Gary E. Mason, Thomas Renaud, Jeffrey Matous
T-Cell Phenotyping Supports the Use of T-Cell Engaging Antibodies for Treatment of Calreticulin Mutated Myeloproliferative Neoplasms
Anna Kuchnio, Elsie Samakai, Eva Hug, Meritxell Balmaña, Lut Janssen, Ricardo Amorim, Ivo Cornelissen, Hussein Shehade, Yann Abraham, Andrea Majoros, Michaël Broux, Isha Taneja, Vince Torti, Laura Barreyro, Azra Agic, Stefan Moritsch, Filippo Benedetti, Felix Rosebrock, Kathryn Packman, Janine Arts, Sonal Patel, Ricardo Attar, Nikki Daskalakis, Oliver Lomas, M. Phillip DeYoung, Oleh Zagrijtschuk, Stefan N. Constantinescu, Robert Kralovics, Ulrike Philippar
Teclistamab Step-Up Dosing and Less Frequent Dosing Schedule in the Real-World Setting – An Analysis of Multicenter Electronic Medical Records
Rahul Banerjee, Hsien-Yen Chang, Dee Lin, Jennifer S. Harper, Alex Z Fu, Nina Kim, Jessica Fowler, Mariana Fernandez, Margaret Doyle, Elissa E. Min, Laura Hester, Dina Gifkins, Bingcao Wu
Treatment Patterns and Molecular Testing Patterns in a U.S.-Based Cohort of Newly Diagnosed and Relapsed/Refractory AML Patients: A Real-World Analysis
Amer M. Zeidan, Gloria Graf, Hsien-Yen Chang, Alex Z. Fu, Heena Mavani, Katherine Daly, Christina Loefgren, Xiaoxiao Lu, Scott Huntington
Copies of these presentations are for personal use only and may not be reproduced without permission from the author of this presentation.